Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors

NCT04214093 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04214093
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04214093 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD0466 in Patients With Advanced Hematologic or Solid Tumors
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Terminated
Start date
December 16, 2019
Completion date
June 18, 2021
Enrollment
9 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors, hematologic malignancies, lymphoma, multiple myeloma